

Tumor Antigen by Immunoassay CA 19-9 (86301) – NCD 190.30

Indications:

Multiple tumor markers are available for monitoring the response of certain malignancies to therapy and assessing whether residual tumor exists post-surgical therapy.

Levels are useful in following the course of patients with established diagnosis of pancreatic and biliary ductal carcinoma. The test is not indicated for diagnosing these two diseases.

Limitations:

These services are not covered for the evaluation of patients with signs or symptoms suggestive of malignancy. The service may be ordered at times necessary to assess either the presence of recurrent disease or the patient's response to treatment with subsequent treatment cycles.

Most Common Diagnoses (which meet medical necessity) *

| | |
|---------------------------|---|
| C22.1 | Intrahepatic bile duct carcinoma |
| C23 | Malignant neoplasm of gallbladder |
| C24.0 | Malignant neoplasm of extrahepatic bile duct |
| C24.1 | Malignant neoplasm of ampulla of vater |
| C24.9 | Malignant neoplasm of biliary tract |
| C25.0 through C25.9 | Malignant neoplasm of all parts of the pancreas |
| C78.7 | Secondary malignant neoplasm of liver and intrahepatic bile duct |
| C78.89 | Secondary malignant neoplasm of other digestive organs |
| D37.6 | Neoplasm of uncertain behavior of liver, gallbladder and bile ducts |
| D37.9 | Neoplasm of uncertain behavior of digestive organ |
| G89.3 | Neoplasm related pain |
| R97.8 | Other abnormal tumor markers |
| Z85.07 | Personal history of malignant neoplasm of pancreas |
| Z85.09 | Personal history of malignant neoplasm of other digestive organs |

*For the full list of diagnoses that meet medical necessity see the Tumor Antigen by Immunoassay CA 19-9 National Coverage Determination 190.30 document

The above CMS and WPS-GHA guidelines are current as of: 04/01/2025.